345 related articles for article (PubMed ID: 25475205)
41. Synthesis and biological evaluation of a novel series of aryl S,N-ketene acetals as antileishmanial agents.
Suryawanshi SN; Kumar S; Tiwari A; Shivahare R; Chhonker YS; Pandey S; Shakya N; Bhatta RS; Gupta S
Bioorg Med Chem Lett; 2013 Jul; 23(13):3979-82. PubMed ID: 23673014
[TBL] [Abstract][Full Text] [Related]
42. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
43. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.
Carter KC; Hutchison S; Boitelle A; Murray HW; Sundar S; Mullen AB
Parasitology; 2005 Dec; 131(Pt 6):747-57. PubMed ID: 16336728
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines.
Sunduru N; Nishi ; Palne S; Chauhan PM; Gupta S
Eur J Med Chem; 2009 Jun; 44(6):2473-81. PubMed ID: 19217698
[TBL] [Abstract][Full Text] [Related]
45. Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.
Kieffer C; Cohen A; Verhaeghe P; Paloque L; Hutter S; Castera-Ducros C; Laget M; Rault S; Valentin A; Rathelot P; Azas N; Vanelle P
Bioorg Med Chem; 2015 May; 23(10):2377-86. PubMed ID: 25846065
[TBL] [Abstract][Full Text] [Related]
46. Chemotherapy of leishmaniasis Part VI: synthesis and bioevaluation of some novel terpenyl S,N- and N,N-acetals.
Suryawanshi SN; Pandey S; Rashmirathi ; Bhatt BA; Gupta S
Eur J Med Chem; 2007 Apr; 42(4):511-6. PubMed ID: 17178176
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation of 2-arylbenzimidazoles targeting Leishmania donovani.
Keurulainen L; Siiskonen A; Nasereddin A; Kopelyanskiy D; Sacerdoti-Sierra N; Leino TO; Tammela P; Yli-Kauhaluoma J; Jaffe CL; Kiuru P
Bioorg Med Chem Lett; 2015 May; 25(9):1933-7. PubMed ID: 25827525
[TBL] [Abstract][Full Text] [Related]
48. Syntheses of new substituted triazino tetrahydroisoquinolines and beta-carbolines as novel antileishmanial agents.
Kumar A; Katiyar SB; Gupta S; Chauhan PM
Eur J Med Chem; 2006 Jan; 41(1):106-13. PubMed ID: 16356594
[TBL] [Abstract][Full Text] [Related]
49. In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani.
Seifert K; Munday J; Syeda T; Croft SL
J Antimicrob Chemother; 2011 Apr; 66(4):850-4. PubMed ID: 21393188
[TBL] [Abstract][Full Text] [Related]
50. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
51. An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani.
Neal RA; Croft SL
J Antimicrob Chemother; 1984 Nov; 14(5):463-75. PubMed ID: 6096347
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines.
Hui X; Desrivot J; Bories C; Loiseau PM; Franck X; Hocquemiller R; Figadère B
Bioorg Med Chem Lett; 2006 Feb; 16(4):815-20. PubMed ID: 16309903
[TBL] [Abstract][Full Text] [Related]
53. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
54. Design and synthesis of novel substituted quinazoline derivatives as antileishmanial agents.
Agarwal KC; Sharma V; Shakya N; Gupta S
Bioorg Med Chem Lett; 2009 Sep; 19(18):5474-7. PubMed ID: 19692240
[TBL] [Abstract][Full Text] [Related]
55. Synthesis of perspicamide A and related diverse analogues: their bioevaluation as potent antileishmanial agents.
Pandey AK; Sharma R; Shivahare R; Arora A; Rastogi N; Gupta S; Chauhan PM
J Org Chem; 2013 Feb; 78(4):1534-46. PubMed ID: 23289499
[TBL] [Abstract][Full Text] [Related]
56. Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.
Das S; Rani M; Pandey K; Sahoo GC; Rabidas VN; Singh D; Das P
J Antimicrob Chemother; 2012 Oct; 67(10):2373-8. PubMed ID: 22761329
[TBL] [Abstract][Full Text] [Related]
57. Discovery of 3,3'-diindolylmethanes as potent antileishmanial agents.
Bharate SB; Bharate JB; Khan SI; Tekwani BL; Jacob MR; Mudududdla R; Yadav RR; Singh B; Sharma PR; Maity S; Singh B; Khan IA; Vishwakarma RA
Eur J Med Chem; 2013 May; 63():435-43. PubMed ID: 23517732
[TBL] [Abstract][Full Text] [Related]
58. In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs.
Jamal Q; Khan NH; Wahid S; Awan MM; Sutherland C; Shah A
Exp Parasitol; 2015 Jul; 154():93-7. PubMed ID: 25911243
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.
Zhu X; Farahat AA; Mattamana M; Joice A; Pandharkar T; Holt E; Banerjee M; Gragg JL; Hu L; Kumar A; Yang S; Wang MZ; Boykin DW; Werbovetz KA
Bioorg Med Chem Lett; 2016 May; 26(10):2551-2556. PubMed ID: 27048943
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of antileishmanial drugs activities in an ex vivo model of leishmaniasis.
Terreros MJS; de Luna LAV; Giorgio S
Parasitol Int; 2019 Aug; 71():163-166. PubMed ID: 30991111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
